Oriel Therapeutics Inc. Signs Development And Licensing Agreement; New Agreement To Allow Development Of Novel Cystic Fibrosis Treatment
10/19/2005 5:09:18 PM
Oriel Therapeutics, an emerging inhaled drug delivery company, today announced that it has signed a development and licensing agreement with an undisclosed U.S.-based biotechnology company to develop a novel therapy for the treatment of cystic fibrosis. This therapy will be based on Oriel Therapeutics' proprietary dry powder inhalation technology incorporating the partner's proprietary compounds that represent a novel mode of action to improve airway function.
comments powered by